Screening for ovarian cancer.
The efficacy of ovarian cancer screening remains to be proven. Advances in ultrasound and tumor marker technology, combined with complex statistical analysis have facilitated 2 large ongoing randomized controlled trials of screening which are powered to determine the impact on mortality. Serum proteomics seems to be a promising area for biomarker discovery, but requires more rigorous validation before it can be used in clinical trials. Current screening tests, clinical trials in the general and high-risk populations, screening acceptability and costs are reviewed in this article.
Rosenthal
Adam N
AN
Institute for Women's Health, University College London, Elizabeth Garrett Anderson Hospital, London, UK. adam.rosenthal@ucl.ac.uk
Menon
Usha
U
Jacobs
Ian J
IJ
D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D010808:Physical Examination; D014463:Ultrasonography; D014599:Uterus / Q000000981:diagnostic imaging
D014408:Biomarkers, Tumor